Inmode Ltd
Research Inmode Ltd (INMD) on Bullrun: valuation model: 48.1% undervalued, market cap USD 863.94M, P/E 12.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerINMD
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Valuation signal48.1% undervalued
- Market capUSD 863.94M
- P/E12.2
- Financial periodQ2 2026
- RevenueUSD 95.59M
- Net incomeUSD 17.06M
- Free cash flowUSD 20.84M
- Gross margin74.8%
Valuation Snapshot
Bullrun's latest valuation model marks Inmode Ltd as 48.1% undervalued; latest market cap is USD 863.94M; P/E is 12.2.
Peer valuation comparison
Latest P/E is 12.2x versus a Healthcare sector median of 24.46x (50.1% below).
Latest P/E is 12.2x versus a Israel median of 24.26x (49.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 370.50M | USD 93.83M | USD 84.29M | 78.5% | 1.43 | USD 302.54M | USD 8.23M | USD 683.20M |
| FY2024 | USD 394.82M | USD 181.28M | USD 132.00M | 80.3% | 2.25 | USD 155.33M | USD 7.82M | USD 703.81M |
| FY2023 | USD 492.05M | USD 197.92M | USD 176.12M | 83.6% | 2.3 | USD 144.41M | USD 9.02M | USD 787.37M |
| FY2022 | USD 454.27M | USD 161.52M | USD 180.00M | 83.8% | 1.89 | USD 97.54M | USD 3.68M | USD 554.62M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 863.94M | 12.2 | n/a | n/a |
| 2025 | 2025-12-31 | USD 930.74M | 10.1 | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.16B | 7.1 | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.85B | 10.6 | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.97B | 17.2 | n/a | n/a |
| 2021 | 2021-12-31 | USD 5.86B | 36.8 | n/a | n/a |
About Inmode Ltd
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Inmode Ltd overvalued or undervalued?
Bullrun's valuation model currently marks Inmode Ltd as 48.1% undervalued.
What is Inmode Ltd's market cap?
Inmode Ltd's market capitalization is USD 863.94M.
What is Inmode Ltd's P/E ratio?
Inmode Ltd's price-to-earnings (P/E) ratio is 12.2.
What does Inmode Ltd do?
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.